Actively Recruiting

Phase 1
Phase 2
Age: 6Months - 21Years
All Genders
NCT05615389

Pilot Study of MC in Paediatric Palliative Care

Led by Murdoch Childrens Research Institute · Updated on 2025-12-24

10

Participants Needed

1

Research Sites

145 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this pilot study is to explore the feasibility and acceptability of a medicinal cannabis clinical trial into easing the symptoms of children undergoing palliative care for non-oncological conditions. The trial will evaluate the study design including recruitment strategy, medication tolerability, duration and outcomes to determine acceptability and feasibility for participating families. The data collected will then be used to design a full-scale multi-centre trial. Participants will be randomly allocated to receive one of two medicinal cannabis products. Neither the participants nor researchers will know the study drug allocation until the end of the trial.

CONDITIONS

Official Title

Pilot Study of MC in Paediatric Palliative Care

Who Can Participate

Age: 6Months - 21Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males and females aged 6 months to 21 years
  • Receiving care in the Victorian Paediatric Palliative Care Program for a non-oncological condition
  • Parent-rated symptom score above threshold for pain, dystonia, or gut dysfunction on the revised Memorial Symptom Assessment Scale
  • No changes in medication or other interventions in the two weeks prior to randomization
  • Participant and family able to comply with protocol requirements as judged by investigator
  • Agreement not to drive for the duration of the study
Not Eligible

You will not qualify if you...

  • Non-English speaking parents
  • History of psychosis, schizophrenia, bipolar disorder, major depressive disorder, or first degree family history of psychosis
  • Taking medications known to interact with medicinal cannabis such as warfarin, mTOR inhibitors, certain anti-cancer agents, high doses of citalopram or escitalopram
  • Abnormal liver function tests (ALT > 3 times upper limit of normal)
  • Current or recent use of illicit drugs or medicinal cannabis within 4 weeks prior to screening
  • Pregnant, intending to become pregnant during the study, or breastfeeding
  • History of significant suicidal thoughts in prior 12 months
  • Life expectancy less than 3 months as judged by investigators
  • Allergy to any components of the study products (e.g., sunflower oil)
  • Diagnosis of a malignant condition

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Royal Children's Hospital / Murdoch Children's Research Institute

Parkville, Victoria, Australia, 3052

Actively Recruiting

Loading map...

Research Team

A

A/Prof Daryl Efron

CONTACT

C

Clinical Trial Coordinator

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

SUPPORTIVE_CARE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here